C.R. Bard Inc. (New Jersey) (BCR)

331.24
1.95 0.59
NYSE : Health Technology
Prev Close 333.19
Open 333.49
Day Low/High 331.24 / 334.03
52 Wk Low/High 223.02 / 337.73
Volume 4.71M
Avg Volume 610.90K
Exchange NYSE
Shares Outstanding 72.89M
Market Cap 24.14B
EPS 7.20
P/E Ratio 43.70
Div & Yield 1.00 (0.00%)
'Fast Money' Recap: Market Slide

'Fast Money' Recap: Market Slide

The trading panel expressed their dismay at the severe drop in the market.

C.R. Bard Upgraded On 2010 Revenue Growth Outlook

Analyst upgrades C.R. Bard shares to 'buy,' expecting company to reach sales growth goal

Medtronic Net Falls 38% on Charges

Medtronic Net Falls 38% on Charges

Medtronic posts a steep earnings decline on a slew of charges, though its sales grew in the first quarter.

Correction: C.R. Bard Executive Pay Story

Correction: C.R. Bard executive pay story

C.R. Bard 1Q Profit Jumps 44 Percent

C.R. Bard's 1st-quarter profit rises 44 percent as restructuring program reduces costs

C.R. Bard CEO Pay Increases 9 Percent In 2008

C.R. Bard CEO Timothy Ring gets $10.5M in 2008 compensation, up 9 percent from year before

'Mad Money Lightning Round': Stick With Bucyrus International

Cramer likes its balance sheet and managment.

Fund Manager Reed Picks 'Obama' Stocks

Fund Manager Reed Picks 'Obama' Stocks

The UMB Scout Stock Fund prepares for changes in the health-care industry under a new administration.

Dividend.com: Exxon Mobil Gushes Big Gains

Dividend.com: Exxon Mobil Gushes Big Gains

The oil giant reported a record quarterly profit despite the drop in crude oil prices.

Top Dividend Plays for the Week

These are the latest companies to increase their dividends.

Analysts' Upgrades, Downgrades: Emulex

See who made what calls.

Jim Cramer's Best Blogs

Jim Cramer's Best Blogs

Catch up on his thinking on the hottest topics of the past week.

Cramer's 'Mad Money' Recap for July 11

Cramer's 'Mad Money' Recap for July 11

The company has a flourishing business in stents, catheters and other medical devices, Cramer says.

Need Defense? Think Medical Supplies

Companies such as C.R. Bard and Becton Dickinson might not be the most glamorous names, but their slow and steady performances may win the race.

Wednesday's Analysts' Upgrades and Downgrades

Wednesday's Analysts' Upgrades and Downgrades

Who made what calls.

Wednesday's Buybacks: C.R. Bard for $500 Million

Here's a list of companies that have recently announced buybacks.

Cramer's 'Mad Money' Recap: Fed Stranglehold

Cramer's 'Mad Money' Recap: Fed Stranglehold

To help offset the Fed's 'intransigence,' Cramer offers his 'Three Bs' defensive portfolio.

Sidelines a Safe Bet

There's no need to get aggressive in either direction in the current environment.

Sears Shows Its Softer Side

Sears Shows Its Softer Side

After a double-top formation, we're not likely to see buyers emerge until the $120s.

Sears Shows Its Softer Side

After a double-top formation, we're not likely to see buyers emerge until the $120s.

Mad Money Mailbag: High Price to Pay for Bard

Mad Money Mailbag: High Price to Pay for Bard

A viewer learns Cramer's take on medical devices company C.R. Bard.

'RealMoney' Radio Recap: Tech Opportunity Knocking

'RealMoney' Radio Recap: Tech Opportunity Knocking

Cramer says look past the hits taken by Intel and Yahoo! for good tech stocks.

Cramer's 'Mad Money' Recap: It's Takeover Time

Cramer's 'Mad Money' Recap: It's Takeover Time

Among companies ripe for corporate conquest are UST and Bard, Cramer says.

Finding Traction in a Slippery Market

Food, health care and consumer nondurables are moving forward in slick conditions.

Take Your Cue From Price Action

The market needs a day or two longer to resolve short-term direction.

Tyco, C.R. Bard End Merger Pact

Tyco, C.R. Bard End Merger Pact

The companies struck a deal valued at $3.1 billion last May.

Tyco's Split-Up Underscores a Failed Strategy

The conglomerate didn't work, and three hyped IPOs look rather mundane.